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Summary Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide
(VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [1231lIP as a radioligand. An initial series
performed at our instituton showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [Ili]VIP. In
this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with
histologically verified colorectal cancer underwent scanning by means of ['23IJVIP (1 gg, approximately 150 MBq). Thirteen patients were free
of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were
free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ
metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and
6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine
physicians in a bJinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of
eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with ['231}IP. Negative VIP scans were obtained in all 13
patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of
four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung
metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the
diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP
receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to
conventional radiological methods.
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Colorectal cancer is among the leading causes of cancer death
worldwide and accounts for about 10% of all cancer deaths. It is
second only to lung cancer in men and to breast cancer in women.
and it is estimated that 1 in 20 persons is affected in Western
countries (Boring et al. 1994: de Cosse et al. 1994: Seidman et al.
1985). The only curative therapeutic option is surgical resection,
whereas oncological intervention in patients with advanced. inop-
erable cancer remains palliative at best (Scheithauer et al. 1993).
Because of the strong association between early detection of
primary/relapsing tumours or metastases and prognosis, exact
determination of the tumour burden is important for the clinical
management of these patients. Imaging methods available include
endoscopy. ultrasound, barium enema as well as computerized
tomography (CT) and magnetic resonance imaging (MRI).
Although these methods have specific roles in the evaluation of
patients with colorectal adenocarcinoma, none of them fuilfils the
criteria of being an 'optimal' approach (Stevenson. 1994) as peri-
toneal carcinosis or small extrahepatic lesions mimicking post-
operative scars (Schlag et al. 1989) might escape detection.
Therefore, the evaluation of additional methods for imaging
colorectal neoplasms and metastases is warranted.
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Recently, various groups have demonstrated (Reubi, 1995:
Virgolini et al. 1994a) that gastrointestinal adenocarcinomas
express high-affinity binding sites for vasoactive intestinal peptide
(VIP). Based on this finding, we have developed a peptide scan
using "21-labelled VIP as a tumour-seeking agent (Virgolini et al.
1994b: 1995). In an initial series, the ability of the tracer to
localize even small adenocarcinomas of the gastrointestinal tract
along with the safety of the agent could be demonstrated at our
institution (Virgolini et al. 1994a, b; 1995: Raderer et al. 1996).
Although in vitro data (Reubi. 1995) have shown the expression of
VIP receptors to some extent also in normal colorectal mucosa.
our results did not indicate tracer uptake in the normal gut mucosa.
In addition, a higher sensitivity for the peptide tracer was found
when compared with an "'In-labelled, commercially available
anti-TAG-72.3 antibody (Raderer et al. 1996).
Based on these findings, we have followed 80 consecutive
patients between July 1994 and December 1996 in order to deter-
mine the diagnostic capability of ['"I]VIP for visualization of
adenocarcinomas ofthe colon and rectum.
PATIENTS AND METHODS
Patients
Eighty consecutive patients (36 women/44 men) with a median
age of 67 years and histologically verified adenocarcinoma of the
colon or rectum were included in the study (forpatient characteris-
tics see Table 1) between July 1994 and December 1996. The
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application of ['23I]VIP was approved by the Ethics Committee of
the University ofVienna, and all patients signed informed consent
according to institutional guidelines.
Patients older than 75 years orindividuals with a severe concur-
rent illness such as psychiatric disorders, florid infections or a
second malignancy were excluded from the study. All patients had
undergone conventional radiological imaging by means of CT to
confirm the presence or absence of cancer and to measure objec-
tively the extent oftumourburden atthe time ofradioimaging. The
maximum time span between conventional imaging and applica-
tion of [123I]VIP was 4 weeks. However, a follow-up CT was
performed 4 and 8 weeks after scanning to check for subclinical
lesions as not yet detectable on conventional imaging in case of
focal tracer accumulation without acorresponding lesion on CT. In
addition, patients thought to be free of tumour at the time ofscan-
ning were also followed for at least 3 months after scanning.
Before injection of the radiotracer, all patients had received full
thyroid gland blockade with sodium perchlorate (400 mg three
times daily for 3 days) and potassium iodide (2 x 65 mg for
2 days) starting the day before the injection oflabelled VIP.
At the time of scanning, 13 patients were free of tmour after
complete resection of Dukes' C cancer, and all patients were
scheduled to receive 5-fluorouracil (FU)-based adjuvant chemo-
therapy. Nine were imaged before the start of tratment, whereas
the remaining four were injected with ['23I]VIP between the treat-
ment cycles. Eight patients presented with primary rectal cancer,
and 14 with locally recurrent tumours (eight rectal cancers, three
sigmoid, one cancer of the colon transversum and two cancers in
the colon ascendens), but were free of metastases as judged by
conventional imaging. Ten patients did not only suffer from
locally recurrent cancers (five rectal cancers, two tumours in the
sigmoid, one transversal cancer and two masses in the middle
abdomen) but also had liver, lung or lymph node metastases.
Disease confined to metastatic sites in liver, lung, bone or lymph
nodes was present in 35 patients. The primary orrecurrent tumours
ranged from 3 to 16 cm, and the size of metastases was between 1
and 13 cm as measured by the maximum diameter on conventional
CT (see Table 1). A total of 14 patients with metastatic disease had
documented polyps in the colon at the time of scanning, and four
ofthese patients had familial polyposis.
Most patients were imaged before the initiation of chemo-
therapy consisting of 5-Fu and leucovorin, only 12 patients (three
patients with recurrent cancers and nine patients with liver metas-
tases) were injected with ['23I]VIP between tratment cycles.
Preparato of radioiodinated VIP
The preparation of['23I1VIP was performed according to established
methods reported previously (Virgolini et al, 1994b). VIP was
generated by a peptide-synthesizing machine and labelled with 123I
using a modified lodogen method [123IlVP was purified by prepar-
ative high-perfornance liquid chromatography (HPLC) (column:
RP C18, 5 jm, 4 x 250 mm, eluent: 74% (v/v) aqueous 0.25 M tri-
ethylammonium formate, pH 3,26% (v/v) acetonitrile at 1 ml min7l)
to obtain a high specific activity. The column eluent passed thrugh
a scintillation radioactivity detector and UV (280 nm) detector in a
series. The system was calibrated with unlabelled VIP and enabled
collection of pure radioiodiated VIP, separated from unlabelled
VIP, reagents and inorganic iodine species. The eluent was evapo-
rated at reduced psure. The product was dissolved in phosphate-
buffered saline containing 0.1% (wlv) Tween 80 (Koch-Light Lab,
T1a I Patien !%afeistis
Number ofpabents 80 (36 women/44 men)
Median age (years) 67 (range 36-75)
Median WHOperbmance status 1 (range0-2)
Median daneter o sia (cm)
PrImaiy twnours 4 (rane 3-7)
L recuret hNnours 6 (range 3-16)
Liver 4.5 (range 1-13)
Lymph nodes 2-4
Lung medases 2-3.5
aAsjudged bythe argestdcameter on convertional CT.
Colnbroke, UK). The labelledproduct wasanalysed usinganalytical
HPLC (cresponding to the p e system, however; using a
dedicated analyfical column) and zone electrphoresis (Wbatman 3
MM paper, 0.1 barbital buffer, pH 8.6, using a field of300V for 10
min). The percentage of unbound iodine (<3% in all preparations)
remained stable over at least 24 h. Before injection, [F'31VIP was
filtered dhough sterile Millex GV 0.2-jm membranes (Millipore,
Milford, MA, USA). ['23I]VIP was adminisd as a single intra-
venous bolus injection in 3 ml of 0.9% sodium chloride solution
(150 MBq; approximately 1 jg ofVIP).
Gamma camera imaging and analysis
Planar and single-photon emission tomography (SPET) studies
were carried out using a large field of view gamma-camera
(Toshiba, Japan, or Picker, USA) equipped with a low-energy
parallel hole collimator. Sequential abdominal images were
recorded every minute for a total of 30 min (matrix 128 x 128
pixels) in the first 30 patients, whereas no sequential imagig was
performed in the following patients. Thereafter, planar images in
anterior, posterior and lateral views of two regions covering the
thorax and the abdomen were acquired at 30 min, 2-4 h (and in
initial studies at 18-24 h) after injection (matrix 256 x 256 pixels;
300-800 kcounts were acquired). For recording and visualization,
standard techniques were applied. A one-headed or three-headed
gamma-camera (Picker Prism 1000 and Picker Prism 3000) was
used for SPET imaging at 2-4 h. Scanning was performed in a
360° circle in 60 steps, 30 s perstep. Afterprocessing using adedi-
cated computer (back projection with a ramp filter, post-filtering
with a low-pass filter), the data were reconstructed in three planes
(coronal, sagittal and tansaxial reconstruction).
RESULTS
Tolerance of [19]VDP
All patients toleratedthe application ofthe tracerwithoutthe occur-
rence ofmajor side-effects. As has beenpublished before (Virgolini
et al, 1994a, 1995; Raderer et al, 1996), the only effect detected
was a short, mostly asymptomatic drop in blood pressure with
return to baseline values within 5-10 min in nine ofourpatients. In
addition, two patients experienced a slight buning sensation at the
injection site during bolus administration of['23I]VIP.
Imaging resufts
Seven of eight primary (87%) and 21 out of 24 (82%) locally
relapsing cancers were imaged with ['23I]VEP Negative VIP scans
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Fgwe 1 SPET rconsuct (tansverse slice) performed 3 h after
injection of the acer, displaying physiooi renal excretion as well as
accumulation of [1231VlP in a primary adenoCarCinoua of the ascending
colon (arrow)
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Figure 2 Transverse SPET reconstructo showing focal tracer uptake
(arrow) indicating the site of metastatic liver disease. Owing to the
klcalizabon of the metastasis, the slices also depict physiolgical lung uptake
in the left lower lobe
were obtained in all 13 patients in whom the cancers had been cura-
tively resected. and no scans were rated false positive in these
patients. All patients with lymph node metastases (four out offour)
and two out ofthree patients with lung lesions showed positive VIP
scans, and 25 out of 28 (89w) patients with liver metastases had
positive imaging results. In contrast to the focal tracer uptake in
malignant sites, no ['23I]VIP accumulation occurred in the docu-
mented adenomatous polyps present in a total of 14 patients.
Figure 3 Ptanar imaging 24 h after injection of[mi]lVlP showing focal tracer
uptake corresponding to a single metastasis in the left lung within normnal
surrounding lung activity. Owing to the presence of a struma diffusa. tracer
uptake can also be seen in the thyroid gland despite prior thyroid gland
blocade
Impact of VIP scanning on staging
In four patients with relapsing cancer. initially indicated only by
rising CEA-levels (three rectal cancers and one tumour in the
colon transversum). the [12-I]VLP scan indicated the presence of
disease without a corresponding lesion on CT. Follow-up CTs
were performed. and malignant lesions appeared at the site ofVIP
accumulation 8-14 weeks later in all fourpatients. Additional liver
metastases could be identified in five patients thought to be
affected with single hepatic lesions seen on conventional CT
imaging. In two patients. the diagnosis of scar tissue instead of a
local recurrence of rectal cancer after combined radiotherapy and
chemotherapy as suggested by CT was indicated by the absence of
['2'I]VIP uptake. Serial follow-up CTs after 4 and 8 weeks showed
no growth ofthe lesions in both cases. and a transrectal fine-needle
biopsy verified the presence of scar tissue without malignant cells
in one patient. whereas the other patient refused this procedure.
Both patients are alive 12 months after initial VIP scanning
without evidence of disease recurrence. and a second VIP scan
performed 8 and 10 months. respectively. after the first one was
also negative.
Results of planar imaging vs SPET results
The results obtained with initial planar scanning differed consider-
ably from SPET reconstructions performed after 2-4 h. Although
initial acquisitions disclosed five out of eight primary and 15 out
of 24 locally relapsing tumours. the final reading of SPET results
identified seven out ofeight and 21 out of 24 lesions respectively.
Planar imaging gave positive results in two out of four patients
with lymph node metastases, whereas all four patients had positive
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scans when SPET reconstructions were evaluatedLThe presence of
liver lesions was detected in 16 patients on planar imaging,
whereas another nine patients had positive SPET images in addi-
tion to planar imaging. In totaL the correct number of metastatic
foci was estimated more accurately in a total of 15 patients with
SPET reconstructions detecting single metastases in the nine
patients with negative planar scans and multiple metastases in
eight patients compared with single foci on planarimagng.
Despite the physiologically occurring accumulation ofthe tracer
in the lungs, two out ofthree cases with known lung metastases
were identified correcdly with SPET reconstructions. In one
patient who had undergone resection of a single lung metastasis,
VIP scaniingmissed a local recurrence in the resection scar. Upon
radioimaging, this patient presented with rising CEA levels but
an odtrwise negative work-up by conventional means. Although
VIP demonstra inhomogeneous lung uptake with a cold spotin
the area of surgery interpreted as scar tissue after surgery, the
cancerous lesion displayed by CT scanning 8 weeks after VIP
scintigraphy (and an initially negative CT) could not be differenti-
ated from the surrounding physiological lung activity. In addition,
a vertebral metastasis present in a patient with liver metastases
was not detected by VIP receptor scanning.
Despite the fact that the last decade has seenimportant discoveries
in terms of uncovering the genetic basis of colorectal cancer
(Kinzler et al, 1991; PeltomAki et al, 1993), the prognosis for
patients diagnosed with advanced disease remains poor. Apart
from surgical resection, no curative therapeutic modality exists at
the moment Therefore, early diagnosis is one ofthe crucial points
in the successful management of colorectal cancer. Despite the
well established role of conventional radiological imaging, the
evaluation of additional methods is warranted to facilitate early
detection and treatment Promising results using monoclonal anti-
bodies or antibody fragments, especially in patients with rising
CEA levels andothrwise negative work-up, have been reported in
the recent literature (Rutgers, 1995; Patt et al, 1994). However,
this approach still has to be considered as experimental. In
summary, according to the literature, about 70% of cancerous
lesions can be visualized in colorectal cancer, and about 10% of
tumour deposits not identified by means of conventional imaging
can be detected (Rutgers, 1995) with the application ofantibodies.
In addition, the use of whole antibodies suffers from some short-
comings, such as impaired tissue penetration, heterogeneous
antigen expression by tumour cells or the development of human
anti-mouse antibodies (Rutgers, 1995). Thus, the use of antibody
fragments (Patt et al, 1994) or application of peptides could be of
advantage in terms ofdiagnostic accuracy.
Our data indicate that [123I]VIP receptor scintigraphy has
prmising clinical potential for the visualization of primary and
recurrent colorectal adenocarcinomas as well as metastatic sites.
In contrast to trials with antibody firgments (Patt et al, 1994)
designed to target specific subgroups of patients, our study was
undertaken to evaluate the performance ofthe novel peptide tracer
in a large cohort ofpatients reflecting the clinical situation as seen
in routine oncological practice. In this series, a high sensitivity for
primary cancers was obtained: seven out of eight primary (87%)
and 21 outof24 (82%) locally relapsing cancers were imaged with
['23I]VWP In fourpatients, locally recurrentdisease couldbe identi-
fied 8-14 weeks before clinical evidence on CT scan. In addition,
no false positive scans in patients operated on for Dukes' C cancer
were obtained, and no focal trar uptake occurred in colonic
polyps. In two patients, ['23I]VIP receptorscintigraphy suggested
the presence of scar tissue instead of recurring rectal cancer as
indicated by initial CT scanning. Liver metastases could be
imaged with a sensitivity of 89% (25 out of 28 patients), and the
presence ofmultiple lesions could be established by radioimaging,
whereas CT scanning indicated only single hepatic lesions in five
patients. In addition, a high sensitivity for imaging abdominal
lymph nodes was found despite thelimited number, with four out
offour patients having positive scans.
However, the use of state-of-the-art single-photon emission
tomography techniques between 2 and 4 h afterinjection proved to
increase the sensitivity of the peptide scan. In total, eight primary
cancers, two cases of lung metasases and two cases of malignant
spread to lymph nodes were seen on SPET reconstrutons that
could not be visualized on planar imaging. In addition, nine more
patients were identified to have liver metastases on SPET recon-
stuctions, and an additional eight patients were diagnosed as
having multipleliver lesions instead ofsingle metastases asjudged
by planar acquisition. Conversely, all lesions imaged by planar
acquisition were also seen on SPET images. Thus, the meticuluous
performance of SPET reconstructions in three planes seems to be
ofimportance for obtaining optimal results with this peptide tracer.
As has been published, the lung is the major organ of [23I]VIP
uptake after intravenous injection. Despite this limitation, the pres-
ence of lung metastases could be confirmed in two out of three
patients on SPET reconstructions.
Taken together, our results add to the accumulating body of
evidence that ['23IIVIP receptor scintigraphy is a highly promising
method for imaging and staging of gastrointestinal adeno-
carcinomas. Apart from clinical application of peptides for
radioimaging, the overexpression of peptide-binding sites could
theoretically offer the potential to apply radiolabelled peptides for
targeted numour therapy. However, despite the capabilities of VIP
as an imaging agent, the high lung uptake does not permit the use
ofthe compound labelled with isotopes suitable for therapy. Thus,
novel compounds with a different binding profile have been
developed at our institution and are currently undergoing clinical
testing.
Furthermore, our data lend support to in vitro results demon-
strating ahigh expression ofVIP receptors in a large percentage of
colorectal adenocarcinomas (Reubi, 1995; Virgolini et al, 1994a).
Although the presence of VIP receptors has also been demon-
stauted in normal gut mucosa, this does not lead to clinically rele-
vant uptake in normal mucosa and consequently does not interfere
with imaging of malignant processes. Although in vitro data
obtained by autoradiography have demonstated relevant amounts
of VIP receptors in all primary tumour samples investigated
(Reubi, 1995), we were able to image the majority of primary
tumours (i.e. approximately 80%). However, it has to be empha-
sized that the majority of patients undergoing VIP receptor scan-
ning had not received chemotherapy before injection ofthe trwer.
Virtually nothing is known about the influence of chemothera-
peutic agents on receptor expression. Despite the limited number
of patients (four patients with adjuvant teatment and 12 patients
with palliative, 5-FU-based therapy), one cannot exclude a nega-
tive impact of cytotoxic agents on radioimaging, providing a
possible explanation for the false negative results obtained. All
patients undergoing adjuvant treatment had negative scans, but
also did not developradiological signs ofmalignancy in a 3-month
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follow-up period afterradioimaging. In contrast, two patients with
locally relapsing cancers and three patients with liver lesions had
negative scans, whereas the remaining seven patients administered
palliative treatment had positive scans. Further investigations to
evaluate the influence of cytotoxic treatment on receptor expres-
sion have been initiated at our institution. In addition, necrotic
changes within tumours or dedifferentiation with loss of VIP
receptor expression in rapidly growing tumours might provide an
additional explanation fornegative scans, as has also beenhypoth-
esized in patients with pancreatic cancer (Raderer et al, 1998)
undergoing VIP scanning.
The application ofradiolabelled VIP is generally safe and offers
the potential ofobtaining results within 2-4 h after injection ofthe
peptide. We conclude that this peptide tracer has the potential to
offer valuable additional information to conventional radiological
imaging in a broad cohort of patients, including subjects with
small cancers or suspected recurrent cancers in scar tissue in the
pelvis resulting from initial surgery.
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